Search Thermo Fisher Scientific
Monitoring the presence of HLA antibodies is essential as part of a pre-and post-transplant testing. HLA, HNA and MICA antibodies are considered risk factors for rejection and allograft loss. Donor-specific anti-HLA antibodies can be developed de-novo after transplantation, a transfusion or pregnancy.
Employing screening kits enables the detection of antibodies, serving as the initial step in the testing process and facilitating ongoing monitoring.
LABScreen Mixed Class I and II is a screening test dedicated to detecting antibodies against A, B and C, DR, DQ and DP antibodies, and MHC Class I related chain A (MICA) — another factor shown to cause transplant rejection. With its ease of use, processing up to 96 samples simultaneously, LABScreen Mixed is well-suited for monthly patient antibody screening in both low and high-throughput laboratories.
LABScreen Multi is an assay that can simultaneously screen for HLA and HNA antibodies, providing an easy and efficient method for donor screening compared to conventional testing methods. HNA 1a, 1b, 1c, 2, 3a, 3b, 4a, 5a and 5b antibodies can be identified, providing the opportunity for laboratories to screen donors and identify these human neutrophil antigens to potentially mitigate the risk of Transfusion-related acute lung injury (TRALI).
LABScreen PRA determines percent PRA and identifies antibody specificities using a panel of color-coded microbeads coated with HLA antigens purified from different cells.
LABScan 100 and LABScan3D flow analyzers allow you to test for Class I and Class II separately or together providing flexible testing options in screening and testing cycles.
For Research Use Only. Not for use in diagnostic procedures.